ATAI
Price
$4.42
Change
+$0.09 (+2.08%)
Updated
Dec 11 closing price
Capitalization
1.61B
104 days until earnings call
Intraday BUY SELL Signals
BEAM
Price
$27.62
Change
+$0.11 (+0.40%)
Updated
Dec 12, 10:55 AM (EDT)
Capitalization
2.79B
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATAI vs BEAM

Header iconATAI vs BEAM Comparison
Open Charts ATAI vs BEAMBanner chart's image
Atai Beckley
Price$4.42
Change+$0.09 (+2.08%)
Volume$1.85M
Capitalization1.61B
Beam Therapeutics
Price$27.62
Change+$0.11 (+0.40%)
Volume$836
Capitalization2.79B
ATAI vs BEAM Comparison Chart in %
View a ticker or compare two or three
VS
ATAI vs. BEAM commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and BEAM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (ATAI: $4.42 vs. BEAM: $27.51)
Brand notoriety: ATAI and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 34% vs. BEAM: 60%
Market capitalization -- ATAI: $1.61B vs. BEAM: $2.79B
ATAI [@Biotechnology] is valued at $1.61B. BEAM’s [@Biotechnology] market capitalization is $2.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, ATAI is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • ATAI’s TA Score: 4 bullish, 6 bearish.
  • BEAM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ATAI.

Price Growth

ATAI (@Biotechnology) experienced а +0.45% price change this week, while BEAM (@Biotechnology) price change was -4.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.31%. For the same industry, the average monthly price growth was +4.75%, and the average quarterly price growth was +65.86%.

Reported Earning Dates

ATAI is expected to report earnings on Mar 26, 2026.

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+1.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.79B) has a higher market cap than ATAI($1.61B). ATAI YTD gains are higher at: 232.331 vs. BEAM (10.927). ATAI has higher annual earnings (EBITDA): -115.96M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. ATAI (95.9M). ATAI has less debt than BEAM: ATAI (9.22M) vs BEAM (155M). BEAM has higher revenues than ATAI: BEAM (60.3M) vs ATAI (2.31M).
ATAIBEAMATAI / BEAM
Capitalization1.61B2.79B57%
EBITDA-115.96M-414.33M28%
Gain YTD232.33110.9272,126%
P/E RatioN/AN/A-
Revenue2.31M60.3M4%
Total Cash95.9M1.15B8%
Total Debt9.22M155M6%
FUNDAMENTALS RATINGS
ATAI vs BEAM: Fundamental Ratings
ATAI
BEAM
OUTLOOK RATING
1..100
517
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3739
P/E GROWTH RATING
1..100
13100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (32) in the null industry is somewhat better than the same rating for ATAI (65) in the Miscellaneous Commercial Services industry. This means that BEAM’s stock grew somewhat faster than ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (84) in the Miscellaneous Commercial Services industry is in the same range as BEAM (100) in the null industry. This means that ATAI’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's SMR Rating (96) in the null industry is in the same range as ATAI (97) in the Miscellaneous Commercial Services industry. This means that BEAM’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (37) in the Miscellaneous Commercial Services industry is in the same range as BEAM (39) in the null industry. This means that ATAI’s stock grew similarly to BEAM’s over the last 12 months.

ATAI's P/E Growth Rating (13) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BEAM (100) in the null industry. This means that ATAI’s stock grew significantly faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAIBEAM
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 23 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signal:
Gain/Loss:
BEAM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGXIX16.930.16
+0.95%
Hartford Global Impact I
WWSYX21.060.18
+0.86%
Westwood Quality SmallCap Fund Ultra
MADVX20.840.16
+0.77%
BlackRock Equity Dividend Instl
VALAX29.770.16
+0.54%
Al Frank Adv
TIOVX17.78-0.03
-0.17%
Nuveen International Opps W

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with MNMD. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
+2.08%
MNMD - ATAI
55%
Loosely correlated
+1.70%
COUR - ATAI
45%
Loosely correlated
+0.61%
VCYT - ATAI
45%
Loosely correlated
-2.56%
RXRX - ATAI
41%
Loosely correlated
-3.98%
IDYA - ATAI
41%
Loosely correlated
-0.24%
More